FIGS Just Gained 49% in a Month: Take Profits, or Buy More?
FIGS stock rose 48.9% in October, outperforming the S&P 500. Q2 revenue grew 28.8% to $196.6M, prompting a full-year growth outlook raise to 20%. Shares trade at 55x forward earnings, with analysts expecting 6% EPS growth in 2027. The company's strong performance and momentum drove gains, but valuation is now premium.
How this was made
The 30-second read
Why it matters
The earnings beat and raised outlook provide fresh positive catalyst, but high forward multiple may limit upside.
Market read
First earnings report of the quarter with new guidance; relevant for traders considering positions in FIGS or the health‑apparel niche.
What to watch
Tariff refund boost to margins may not be repeatable; international revenue growth sustainability uncertain.
Background
FIGS is a healthcare apparel company that has been rallying on momentum and improving fundamentals.
Ticker impact
Q2 earnings showed revenue of $196.6M (+28.8% YoY) and EPS beat, prompting management to raise full-year revenue outlook to ~20%.
potential modest upside as investors digest the beat, but likely pressure from valuation concerns.
Strong earnings and guidance lift sentiment, yet 55x forward earnings suggests some downside risk.
Market effects
Highlights growth potential in healthcare apparel, may boost peer sentiment.
U.S. small‑cap health‑tech segment sees renewed interest.
Limited to U.S. equity markets.
Counterpoint
Valuation is stretched; a pullback could occur despite earnings beat.
Key entities
- ExecutiveTrina Spear
CEO of FIGS who highlighted traction across the business.



